
    
      The purpose of this study is to evaluate the long-term safety of the IN.PACT™ AV Access Drug
      Coated Balloon (DCB) for treatment of subjects presenting with de novo or non-stented
      restenotic obstructive lesion of native arteriovenous dialysis fistulae (AVF) in the upper
      extremity. Patients will be followed for five years. The IN.PACT™ AV Access PAS 002 is
      required by the Food and Drug Administration (FDA) as a condition of product approval. This
      study is conducted within Medtronic's post market surveillance platform.
    
  